2020 American Transplant Congress
The Trend of Non-Utilization and Decline of Hepatitis C Virus Antibody-Positive Deceased Donor Kidneys
*Purpose: With more transplant centers are accepting hepatitis C virus infected (HCV+) deceased donor kidneys (dHCV+), the trend of non-utilization and decline of these organs…2020 American Transplant Congress
Hepatitis C and Racial Disparity in Liver Transplant Waitlist Additions: Separate Not Equal
*Purpose: In 2014, direct-acting antivirals (DAAs) became available as a treatment option for Hepatitis C Virus (HCV) with successful results. Since the implementation of DAAs,…2020 American Transplant Congress
Survey of Clinician Opinions on Use of Organ Transplants from Hepatitis C Virus Positive Donors: Identifying & Overcoming Barriers
*Purpose: Increasing the use of Hepatitis C Virus (HCV) viremic (Nucleic Acid Testing (NAT)+) donor organs for HCV uninfected (HCV-) patients is a potential approach…2020 American Transplant Congress
Hepatitis C-Infected Donors and Hepatitis C-Infected Recipients: Analysis of Renal Transplant Outcomes
*Purpose: Increased utilization of hepatitis C virus infected organs could reduce the supply demand mismatch in organ transplantation. At this time, there is little data…2020 American Transplant Congress
Re-Transplantation Outcomes in the United States Before and after DAA-Introduction
Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: The success of direct-acting antiviral (DAA) therapy has led to the widespread treatment of HCV and near-universal cure for chronically infected patients and improved…2020 American Transplant Congress
Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kideney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous trials in kidney transplantation (KT) have described a 12-week course of direct-acting anti-viral drugs (DAA) to treat HCV transmission from infected donors to…2020 American Transplant Congress
Multi-Center, Open-Label Trial of Pre-Emptive Glecaprevir/Pibrentasvir (G/P) to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus (MYTHIC)
*Purpose: Kidneys from Hepatitis C virus (HCV)-infected deceased donors continue to be discarded at high rates despite small, successful studies of HCV-viremic donors into uninfected…2020 American Transplant Congress
Utilization of Hepatitis C Positive Organs in Kidney Transplantation
Ochsner Medical Center, New Orleans, LA
*Purpose: The efficacy of direct acting antivirals (DAAs) in HCV has cleared the path for the use of HCV positive donor kidneys into negative recipients.…2020 American Transplant Congress
Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients
New York Medical College/ Westchester Medical Center, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV-positive solid organ to an uninfected patient who is on the transplant waiting list and might otherwise…2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 28
- Next Page »